Some people have asked, “Your ‘cure’ works in theory, but does it work in practice?” The answer is, “Yes!!!” The key point is that fetal hemoglobin (HbF) has been shown to be preventive for sickle cell disease in nature, in many labs around the world, in many, many repeated experiments and patient trials over the last thirty years. The problem is that no one has figured out how to stimulate this hemoglobin switch in humans without gene therapy, a bone marrow/stem cell transplant, or use of toxic drugs – all of which are dangerous, expensive, and not available to 99.99% of the world’s sufferers. This is what we have now done: found a safe way to induce the HbF switch. We have found a natural, small, stable human protein that will produce this Hb switch (a) in a test tube, (b) in living primate and human cells, (c) in transgenic mice carrying and expressing the human H-ferritin gene, and (d) in forming red bllod cells obtained from pediatric sickle cell patients. All in all, we have performed almost 200 experiments of 50 different types/designs, each experiment replicated 2-to-10 times by 2, 3, or 5 different investigators – all consistently pointing to this same conclusion and its safety. And we have devised 4 ways to deliver this cure! Now, we need the funds to prove its safety in animals, so that we can then start human trials. We can provide the hope, the science, and the safety; you can help us get the necessary funds.
Our cure has been peer-reviewed via Publications & Patents, Grants Awarded, and invitations for International Presentations.
Publications & Patents: PDF files of a List of 25 Publications; a key paper that established the principle of the cure; and our Patent issued in the U.S., the European Union(10 countries), and Australia, are attached.
Grants Awarded: A PDF file of an NIH-form 4-page bio-sketch is attached, with the last two pages listing NIH and other nationally-competitive grants. Dr. Broyles’ curriculum vitae is also attached.
International presentations: PDF files of abstracts of nine invited, international presentations (2003 through 2009) are attached.